Skip to main content

Parasympathomimetics — Legacy and Specialty Uses

Parasympathomimetics in urology — the direct muscarinic agonist bethanechol and the cholinesterase inhibitors neostigmine, pyridostigmine, and distigmine — are the classic pharmacologic approach to detrusor underactivity (DUA), nonobstructive urinary retention, and neurogenic bladder. The evidence has never been strong: the most recent systematic reviews call the data "inadequate to draw clear conclusions," and a 2007 review went further, stating the available literature does not support the use of parasympathomimetics for underactive bladder.[1][2][3] They remain in the legacy category because no better pharmacologic alternative exists — modern urology still has no approved therapy that reliably augments detrusor voiding contraction strength.[3][23]

For the standard framework — muscarinic-receptor physiology, bethanechol dosing per FDA label, contraindications, and the role of CIC — see the Cholinergic agonists hub. This article focuses on the legacy and specialty-use material that does not belong in the main hub: the Bethanechol Supersensitivity Test, electromotive intravesical bethanechol, the Japanese distigmine experience, and the emerging 2025 pyridostigmine RCTs that are beginning to revive interest in this class.

Classification — Direct vs Indirect​

ClassAgentsMechanism
Direct muscarinic agonistsBethanechol (FDA-approved for urology)Quaternary amine; directly stimulates M₃ detrusor receptors; resistant to cholinesterase hydrolysis; does not cross the BBB[4]
Indirect — reversible AChE inhibitorsNeostigmine, pyridostigmineInhibit ACh hydrolysis → ↑ synaptic ACh at parasympathetic terminals; require intact parasympathetic innervation to work[5][15][17]
Indirect — long-acting AChE inhibitorDistigmine (Japan)Bis-carbamate with strong bladder-AChE binding; potentiation persists ≥ 12 h after systemic clearance (plasma t½ 0.7 h)[6][7][8][22]

The duration difference is the clinical story for distigmine — a single dose produces sustained bladder-contraction augmentation far outlasting its plasma concentration, and this does not extrapolate from neostigmine or pyridostigmine (~3 h potentiation after washout).[8]

Bethanechol — Historical Diagnostic Roles​

Bethanechol's role as a diagnostic probe of the bladder predates its role as a therapeutic — and much of the legacy literature is diagnostic, not therapeutic.

The Bethanechol Supersensitivity Test (BST)​

The BST was introduced to distinguish neuropathic from non-neuropathic detrusor areflexia using Cannon's law of denervation supersensitivity — a denervated muscle responds disproportionately to its agonist. The test protocol:

  • Subcutaneous 2.5–5 mg bethanechol during cystometry
  • A rise in intravesical pressure of > 15 cm H₂O above baseline suggests denervation supersensitivity → neurogenic etiology

The historical evidence:

StudynFindings
Pavlakis 19836398% sensitivity, 100% specificity for neuropathic areflexia[11]
Sidi 19885790% sensitivity, 95.6% specificity; combined with rhabdosphincter EMG and bulbocavernosus reflex latency → accuracy ~ 100%[10]
Blaivas 1980—24% false-negative rate, 50% false-positive rate — "insufficient for diagnosis alone"[12]
Wheeler 1988—Documented positive BST in neurologically normal patients — further eroded its specificity[13]

The test is now largely of historical interest. Modern MRI, urodynamics, and neurophysiologic assessment have displaced it — but the concept of pharmacologic provocation of detrusor contractility informed the more modern electromotive test below.[13]

Electromotive intravesical bethanechol​

A modernization: intravesical bethanechol 20 mg in 150 mL saline delivered via pulsed electromotive current through an electrode catheter. In the Riedl 2000 series of 45 patients with detrusor areflexia:[14]

  • 24 / 26 patients with neurologic disease showed mean pressure increase of 34 cm H₂O
  • Only 3 / 11 patients with chronic bladder distension without neurologic disease responded
  • Oral bethanechol restored voiding in 9 / 11 electromotive-positive responders and 0 / non-responders

This effectively inverts the old BST — rather than asking "is this neurogenic?" the electromotive test asks "will this patient respond to oral bethanechol?" — and does so with a predictive, not descriptive, value. It has not been widely adopted but remains the most rigorous predictive test of bethanechol responsiveness in the modern literature.[14]

Bethanechol — Therapeutic Evidence Today​

The aggregate picture is weak.[1][2]

SourceFindings
Moro 2022 SR/meta (12 trials, n = 3,024)Statistically significant reduction in patients with urinary retention (RR 0.55, 95% CI 0.3–0.98); significant reduction in PVR at ≤ 1 week (MD −77.5 mL); authors concluded overall evidence insufficient for firm evidence-based conclusions[1]
Barendrecht 2007 SR (10 RCTs)3 positive / 6 negative / 1 harmful; "evidence does not support use"[2]
Buckley-Lapitan Cochrane (POUR)Cholinergic agents + sedatives showed significant association with spontaneous voiding (RR 1.39; 95% CI 1.07–1.82), but significant heterogeneity[5]
Gaitonde NAMCS 2003–2013Bethanechol prescribed in 0.8% of relevant visits — 92% of prescriptions by urologists, 79% continued from prior prescriber; mean age 62.3, predominantly women, for detrusor atony (35%), retention (20%), neurogenic bladder (18%)[9]

The Gaitonde data are striking — bethanechol is a drug that urologists continue to prescribe despite knowing the evidence is weak, largely because DUA has no better pharmacologic answer. The drug's persistent use is itself a window on the unmet need.[3][9]

warning

Critical safety concern: if the external sphincter fails to relax while bethanechol contracts the bladder, urine can be forced retrograde up the ureter, causing vesicoureteral reflux and — in the setting of bacteriuria — ascending pyelonephritis.[4] Exclude bladder outlet obstruction and confirm reasonable sphincter coordination before initiating. For the full contraindication list and dosing, see the Cholinergic agonists hub.

Neostigmine — Specialty Perioperative Use​

Neostigmine's urologic footprint is limited to one clinical niche and one preclinical signal.

Postoperative urinary retention after spinal anesthesia​

Senapathi 2018 RCT — n = 36 post-spinal-anesthesia patients, IM neostigmine 0.5 mg vs placebo:[15]

  • Median time to first voiding 40 min (range 20–70) on neostigmine vs 75 min (55–135) control (p ≤ 0.05)
  • Time to first voiding after the spinal block 280.8 vs 364.2 min (p ≤ 0.05)

The effect size is real, but the clinical relevance is limited — most POUR resolves with time and single-catheterization, and neostigmine's cholinergic burden (bradycardia, bronchospasm, GI cramping) is a real perioperative cost.

Diabetic bladder dysfunction — preclinical​

In a rat model of diabetic cystopathy, neostigmine potentiated electrical-field-stimulation–induced bladder contractions more in diabetic strips than in controls, suggesting that elevated bladder cholinesterase activity may contribute to DUA in late-stage diabetic bladder, and that AChE inhibition could become a therapeutic target in this specific population.[16] This has not translated into human trials.

Pyridostigmine — The Emerging Agent​

Two 2025 randomized controlled trials — the best evidence this class has produced — have renewed interest in pyridostigmine for BPH-related voiding dysfunction.

Post-TURP underactive bladder​

Zeinelabden 2025 double-blind RCT — n = 66 BPH patients with preoperative UAB undergoing TURP, randomized postoperatively to pyridostigmine 120 mg/day × 3 months vs placebo:[18]

  • Significant improvement in IPSS (p = 0.001)
  • Significant QoL improvement (p < 0.05)
  • Uroflowmetry and PVR improvements vs placebo

This is the strongest pharmacologic signal for post-TURP underactive bladder in the modern literature — a clinical scenario where durable improvement is otherwise disappointing.

Acute urinary retention due to BPH​

Mohamed 2025 RCT — n = 140, first-episode AUR due to BPH, pyridostigmine 60 mg/day + silodosin 8 mg vs silodosin alone:[19]

  • Successful trial without catheter (TWOC): 82.9% vs 67.1% (combination superior)
  • Significant IPSS and uroflowmetry improvement at 2 wk and 3 mo (p = 0.001, p = 0.003)

For the reconstructive / functional urologist this is the relevant bottom line: add-on pyridostigmine + α-blocker for first-episode AUR may meaningfully improve TWOC success — a result that deserves independent replication but is mechanistically plausible.

Autonomic failure with combined orthostasis and bladder dysfunction​

  • Yamamoto 2006 case report — 66-year-old man with autonomic failure: pyridostigmine 180 mg/day improved both orthostatic hypotension and underactive detrusor bladder dysfunction[20]
  • The cholinergic side-effect profile (urinary urgency, ↑ GI motility) is often therapeutically advantageous in the autonomic-failure population with concurrent constipation[21]

Pyridostigmine is contraindicated in mechanical urinary obstruction — exclude it before adding pyridostigmine to an α-blocker in any BPH scenario.[17]

Distigmine — The Japanese Option​

Distigmine (Japan, approved for DUA, myasthenia gravis, glaucoma) is pharmacologically distinct from other AChE inhibitors:

  • 0.1 mg/kg IV increases maximum intravesical pressure at micturition reflex for ≥ 12 h — despite plasma levels undetectable after 6 h (elimination t½ 0.7 h)[22]
  • Compared head-to-head with neostigmine, pyridostigmine, and ambenonium in guinea-pig detrusor, distigmine's potentiating effect was significantly more sustained (> 12 h vs ~ 3 h)[8]
  • Mechanistically, distigmine selectively potentiates the cholinergic component of parasympathetic nerve–induced bladder contraction without affecting the purinergic (ATP-mediated) component[6][7]

Distigmine is not available in the US or most of Europe — but its pharmacology is the closest thing to a mechanistically sound once-daily cholinergic agent, and the Obara 2017 laboratory work is often cited as the rationale for renewed interest in the class.[6][7][8][22]

Evidence Summary​

AgentClassUrologic FDA statusBest-supported useEvidence quality
BethanecholDirect muscarinic agonistFDA-approved — postoperative / postpartum nonobstructive retention; neurogenic atony[4]DUA, urinary retention, neurogenic bladder (historical)Low — Moro 2022 meta signal[1]; Barendrecht 2007 SR negative[2]
NeostigmineReversible AChE inhibitorNone urologicPOUR after spinal anesthesia; preclinical diabetic bladderVery low — Senapathi n = 36 RCT[15]
PyridostigmineReversible AChE inhibitorNone urologicPost-TURP UAB; add-on for BPH AUR (with α-blocker); autonomic failureLow–moderate and rising — two 2025 RCTs[18][19]
DistigmineLong-acting AChE inhibitorApproved in Japan for DUADUA, neurogenic bladder (Japan only)Preclinical mechanistic strong[6][7][8][22]; clinical data regional

Practical Pearls​

  • Exclude outlet obstruction before prescribing any of these. The uniform, worst-case failure mode is detrusor-against-outlet pressure rise, with risk of reflux, upper-tract damage, and — in SCI patients — autonomic dysreflexia.[4]
  • CIC remains the gold standard for chronic atonic bladder. No parasympathomimetic outperforms well-supported intermittent catheterization for bladder emptying.[3]
  • Atropine 0.6 mg SC / IV is the universal antidote for cholinergic crisis, repeatable every 2 h as needed.[4]
  • The Bethanechol Supersensitivity Test is of historical interest only. Quote Pavlakis and Sidi if asked; quote Blaivas and Wheeler to explain why we do not use it anymore.[10][11][12][13]
  • The electromotive intravesical test (Riedl 2000) is the modern successor — and the most rigorous predictor of who will actually benefit from oral bethanechol therapy.[14]
  • Pyridostigmine + α-blocker is worth knowing about for first-episode BPH AUR — Mohamed 2025 showed 82.9% vs 67.1% TWOC success.[19] Needs independent replication before becoming standard, but the signal is real.
  • Pyridostigmine in autonomic failure is the rare case where the side-effect profile (↑ GI motility, urinary urgency) is therapeutically desired.[20][21]
  • Distigmine does not exist in the US pharmacopeia — but its 12-hour potentiation half-life is the mechanistic proof-of-concept for why once-daily cholinergic augmentation could work if a suitable agent is developed.[8][22]
  • The DUA pharmacologic pipeline is active — acotiamide, ASP8302, neurokinin-2 agonists, TRPV-4 modulators are all under investigation.[23] For now, though, this class is the best pharmacologic answer we have, and it is not a good one.

References​

1. Moro C, Phelps C, Veer V, et al. "The effectiveness of parasympathomimetics for treating underactive bladder: a systematic review and meta-analysis." Neurourol Urodyn. 2022;41(1):127–139. doi:10.1002/nau.24839

2. Barendrecht MM, Oelke M, Laguna MP, Michel MC. "Is the use of parasympathomimetics for treating an underactive urinary bladder evidence-based?" BJU Int. 2007;99(4):749–752. doi:10.1111/j.1464-410X.2006.06742.x

3. Drake MJ, Williams J, Bijos DA. "Voiding dysfunction due to detrusor underactivity: an overview." Nat Rev Urol. 2014;11(8):454–464. doi:10.1038/nrurol.2014.156

4. US Food and Drug Administration. Bethanechol Chloride — prescribing information. Updated 2024-01-22.

5. Buckley BS, Lapitan MC. "Drugs for treatment of urinary retention after surgery in adults." Cochrane Database Syst Rev. 2010;(10):CD008023. doi:10.1002/14651858.CD008023.pub2

6. Obara K, Kobayashi Y, Chino D, Tanaka Y. "Effect of distigmine on the contractile response of guinea pig urinary bladder to electrical field stimulation." Eur J Pharmacol. 2017;809:209–214. doi:10.1016/j.ejphar.2017.05.031

7. Obara K, Kobayashi Y, Chino D, Tanaka Y. "Effects of distigmine on electrical field stimulation-induced contraction of mouse urinary bladder smooth muscles." Pharmacology. 2017;99(3-4):106–113. doi:10.1159/000452222

8. Obara K, Ogawa T, Chino D, Tanaka Y. "The long-lasting enhancing effect of distigmine on acetylcholine-induced contraction of guinea pig detrusor smooth muscle correlates with its anticholinesterase activity." Biol Pharm Bull. 2017;40(7):1092–1100. doi:10.1248/bpb.b17-00175

9. Gaitonde S, Malik RD, Christie AL, Zimmern PE. "Bethanechol: is it still being prescribed for bladder dysfunction in women?" Int J Clin Pract. 2019;73(8):e13248. doi:10.1111/ijcp.13248

10. Sidi AA, Dykstra DD, Peng W. "Bethanechol supersensitivity test, rhabdosphincter electromyography and bulbocavernosus reflex latency in the diagnosis of neuropathic detrusor areflexia." J Urol. 1988;140(2):335–337. doi:10.1016/s0022-5347(17)41596-5

11. Pavlakis AJ, Siroky MB, Krane RJ. "Neurogenic detrusor areflexia: correlation of perineal electromyography and bethanechol chloride supersensitivity testing." J Urol. 1983;129(6):1182–1184. doi:10.1016/s0022-5347(17)52629-4

12. Blaivas JG, Labib KB, Michalik SJ, Zayed AA. "Failure of bethanechol denervation supersensitivity as a diagnostic aid." J Urol. 1980;123(2):199–201. doi:10.1016/s0022-5347(17)55853-x

13. Wheeler JS, Culkin DJ, Canning JR. "Positive bethanechol supersensitivity test in neurologically normal patients." Urology. 1988;31(1):86–89. doi:10.1016/0090-4295(88)90584-5

14. Riedl CR, Stephen RL, Daha LK, et al. "Electromotive administration of intravesical bethanechol and the clinical impact on acontractile detrusor management: introduction of a new test." J Urol. 2000;164(6):2108–2111.

15. Senapathi TGA, Wiryana M, Subagiartha IM, et al. "Effectiveness of intramuscular neostigmine to accelerate bladder emptying after spinal anesthesia." Ther Clin Risk Manag. 2018;14:1685–1689. doi:10.2147/TCRM.S176281

16. Mustafa S, Ismael HN. "Reactivity of diabetic urinary bladder to the cholinesterase inhibitor neostigmine." Urology. 2014;84(6):1549.e1–5. doi:10.1016/j.urology.2014.08.019

17. US Food and Drug Administration. Pyridostigmine Bromide — prescribing information. Updated 2025-12-23.

18. Zeinelabden KM, El-Shazly M, Alorabi A, et al. "The efficacy of pyridostigmine therapy after transurethral resection of prostate in cases with underactive urinary bladder: prospective randomized trial." World J Urol. 2025;43(1):473. doi:10.1007/s00345-025-05842-8

19. Mohamed AG, Badawy HF, Said ASA, et al. "Additive value of pyridostigmine to silodosin in the management of acute urinary retention secondary to benign prostatic hyperplasia: a randomized controlled trial." J Clin Med. 2025;14(3):674. doi:10.3390/jcm14030674

20. Yamamoto T, Sakakibara R, Yamanaka Y, et al. "Pyridostigmine in autonomic failure: can we treat postural hypotension and bladder dysfunction with one drug?" Clin Auton Res. 2006;16(4):296–298. doi:10.1007/s10286-006-0358-z

21. Freeman R, Abuzinadah AR, Gibbons C, et al. "Orthostatic hypotension: JACC state-of-the-art review." J Am Coll Cardiol. 2018;72(11):1294–1309. doi:10.1016/j.jacc.2018.05.079

22. Obara K, Chino D, Tanaka Y. "Distigmine bromide produces sustained potentiation of guinea-pig urinary bladder motility by inhibiting cholinesterase activity." Biol Pharm Bull. 2017;40(6):807–814. doi:10.1248/bpb.b16-00901

23. Sinha S, Cruz F, Cuenca EM, et al. "Is it possible to regenerate the underactive detrusor? Part 1. Molecular and stem cell therapies targeting the urinary bladder and neural axis — ICI-RS 2024." Neurourol Urodyn. 2025;44(3):577–584. doi:10.1002/nau.25597